

FDA

iGΥ DΦMYού የኋላ በVAGT

www.FDA.gov/COVID19vaccines
#FDAAvaccineFacts

1 FDA's EUA for the Pfizer-BioNTech COVID-19 vaccine was based on data from the Phase 3 trial (BNT162b2) showing that the vaccine was 95% effective at preventing COVID-19. The trial included over 43,000 participants from the United States, Canada, Argentina, Brazil, Chile, Mexico, South Africa, and the United Kingdom. The study showed that the vaccine induced a strong immune response and provided protection against symptomatic COVID-19. The FDA approved the vaccine under an Emergency Use Authorization (EUA) on December 11, 2020.

2 The FDA authorized the Moderna COVID-19 vaccine (Moderna Vaccine) under an Emergency Use Authorization (EUA) on December 18, 2020. The vaccine was developed by the National Institutes of Health (NIH) and the Biotechnology and Research Institute (BRI). The vaccine uses messenger RNA (mRNA) technology to teach the body's immune system to recognize and fight off the SARS-CoV-2 virus. The vaccine has been shown to be highly effective in preventing COVID-19, with a reported efficacy rate of approximately 94.5%. The FDA authorized the vaccine under an Emergency Use Authorization (EUA) on December 18, 2020.

ክፍል 1: FDA ከተማውን ስርዓት እና መግለጫ

የደንብ የደንብ ስርዓት እና መግለጫ

አዲስ አበባ የደንብ ስርዓት እና መግለጫ

የደንብ የደንብ ስርዓት እና መግለጫ